Genisphere and University Hospitals Collaborate on Novel Pancreatic Cancer Treatments

HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ -- Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership to study and develop unique strategies to treat pancreatic cancer. According to their agreement, investigators will optimize 3DNA®-based therapeutics designed to target and kill pancreatic tumors. Projects will include delivering a variety of therapeutic cargos, including small molecules and siRNA, formulated with pancreatic tumor-targeting molecules on Genisphere's 3DNA® nanocarrier.

5d657881c5bf9.jpg

Jordan Winter, MD, Chief of the Division of Surgical Oncology at University Hospitals Cleveland Medical Center and Director of Surgical Services at UH Seidman Cancer Center, is the lead researcher on the project. He said "My lab studies the harsh, nutrient-deprived microenvironment of pancreatic cancer to exploit metabolic vulnerabilities. By specifically targeting these hypoxic pathways in a multifaceted approach, we can shut down tumor progression. I see our work with Genisphere leading us down a path to the clinic, and commercial development of a lead candidate for the treatment of pancreatic cancer."

Genisphere's Chief Science Officer, Bob Getts, stated, "We are eager to take the next step from prior data generated together, to investigate alternative strategies for pancreatic cancer treatment. Dr. Winter has strong rationale and evidence for disrupting multiple points along the same biological pathway using different therapeutic molecules and Genisphere has a wide breath of success adapting the 3DNA platform to various modalities:  bispecifics, siRNA, small drugs.  Therefore we are aligned in this multifaceted strategy and by combining capabilities and expertise we can jointly develop a commercial asset, one will be something we take into the clinic."

About Genisphere
Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and crosslinked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead programs based on 3DNA® nanotechnology. For more information, please visit Genisphere.com.

For more information contact:
Jessica Bowers
Marketing Communications, Genisphere
215-996-3027
220480@email4pr.com

About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 50 health centers and outpatient facilities, and 200 physician offices in 16 counties throughout northern Ohio. The system's flagship academic medical center, University Hospitals Cleveland Medical Center, located in Cleveland'sUniversity Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; University Hospitals Harrington Heart & Vascular Institute, a high-volume national referral center for complex cardiovascular procedures; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is one of the largest employers in Northeast Ohio with 28,000 physicians and employees.

Advancing the Science of Health and the Art of Compassion is UH's vision for benefitting its patients into the future, and the organization's unwavering mission is To Heal. To Teach. To Discover. Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, visit UHhospitals.org.

For more information contact:
Jeannine Denholm
Media Relations 
216-844-2555
220480@email4pr.com

If you would rather not receive future communications from eReleases, let us know by clicking here.
eReleases, 10640 Jones Rd, Kingsville, MD 21687 United States

open?upn=XsimBmU6vYsZ-2BKrRy-2F67493xR-2BFOOLjX6Wq20b6qrEEJYJben93pdi7xuFz-2F8NSjWfAP1A9-2FsdHhmXrkb8KRw6gn7NIyqA1eEbcBa13-2FK01AFUceTFl3jtOLZClCOicN8kvkZXNGtq8e7ZrKMYIfE3Ta0jzsjN4fTJnFGjxYeSuCfhFX-2FMimvayZW-2BSpK2ikGyKJduPNe-2BT9Ybwy-2B9w3c8SdapIUN7wVc4-2BckVOjw4Jewo9cPXzKzijicajIE1JKvI-2FVBRklcPDojT93jPZiuZNsAZ35o3rSZFd91BwgN8RG2yhp0MMt4BMd2LB7lmYZlJNYKpqShnx4ss6ueAfWvqMmxFYL3Mi2aTJo4zAx4Dk-3D

Genisphere and University Hospitals Collaborate on Novel Pancreatic Cancer Treatments

Genisphere and University Hospitals Collaborate on Novel Pancreatic Cancer Treatments

Cancer-News

1 month
28 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
Category: Acute Lymphoblastic Leukemia
31 Views
Stan 1 month
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Category: Acute Lymphoblastic Leukemia
18 Views
Cancer-News 1 month
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
Category: Acute Lymphoblastic Leukemia
29 Views
Cancer-News 1 month
IPS based approach for treating virus-induced tumors
IPS based approach for treating virus-induced tumors
Category: Acute Lymphoblastic Leukemia
9 Views
Cancer-News 1 month
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Category: Acute Lymphoblastic Leukemia
39 Views
Cancer-News 1 month
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER  PATIENT GROUP AT WCLC 2019
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER PATIENT GROUP AT WCLC 2019
Category: Acute Lymphoblastic Leukemia
24 Views
Cancer-News 1 month
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Category: Acute Lymphoblastic Leukemia
13 Views
Cancer-News 1 month
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Category: Acute Lymphoblastic Leukemia
23 Views
Cancer-News 1 month
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Category: Acute Lymphoblastic Leukemia
24 Views
Cancer-News 1 month
Will advances in AI lead to more effective screening practices for ovarian cancer?
Will advances in AI lead to more effective screening practices for ovarian cancer?
Category: Acute Lymphoblastic Leukemia
21 Views
Cancer-News 1 month